Drugs / POLYGLYCONATE
POLYGLYCONATE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01623232 | Oct 2012 → Nov 2013 | — | US Department of Veterans Affairs | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2007-05-23 | CEL-SCI Corporation | Results CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals cel-sci.com ↗ |
| 2007-05-01 | CEL-SCI Corporation | Results CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals cel-sci.com ↗
CEL-1000 alone increased the immune response against hepatitis B antigen, and that the combination of CEL-1000 with MAS-1, a proprietary water-in-oil adjuvant delivery system owned by Mercia Pharma, induced highly significant increases in specific anti-HBV (hepatitis B virus) antibodies. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2007-05-23 | CEL-SCI Corporation | CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals cel-sci.com ↗ |
| 2007-05-01 | CEL-SCI Corporation | CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals cel-sci.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POLYGLYCONATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107966 ↗ |
| Known as | MAS-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01623232 ↗ |
| Known as | Maxon | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107966 ↗ |
| Modality | Small molecule | — CHEMBL2107966 ↗ |
| Route | Intramuscular | “Vaccines will be administered IM in the deltoid muscle.” NCT01623232 ↗ |